Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4310 [18F]AlF-NOTA-octreotide as tracer for somatostatin receptor PET/CT: Retrospective analysis of the clinical use in 288 neuroendocrine tumour patients

Introduction: [18F]AlF-NOTA-octreotide has emerged as a reliable tracer for somatostatin receptor (SSTR) PET/CT in patients with neuroendocrine neoplasms (NENs). Although effective and logistically advantageous, there remains limited data on its routine clinical application, particularly for specific NEN subtypes (e.g. NET G3).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Dekervel J, Cleeren F, Goffin K, Dooms C,

Keywords: [18F]AlF-NOTA-octreotide, routine clinical use, neuroendocrine tumour, somatostatin receptor, PET/CT imaging,

#4050 PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,

#3808 Comparison of [18F]AlF-NOTA-JR11 with [68Ga]DOTA-JR11 PET/MRI in models, mice, and neuroendocrine tumor patients

Introduction: Compared with [68]Ga, [18]F has the advantages of high production yield, shorter positron range, and favourable half-life allowing for centralized production and distribution to distant centers.

Conference:

Presenting Author: Yu J

Authors: Ding X, Meng X, Xie Q, Yu J,

Keywords: [18F]AlF-NOTA-JR11, [68Ga]DOTA-JR11, neuroendocrine tumor, PET/MRI,

#3147 Synthesis, preclinical evaluation and a pilot clinical imaging study of [18F]AlF-NODA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE

Introduction: [68Ga]Ga (87% β+, 0.83Mev, T1/2=68min) is widely used associate with SSTR agonist and antagonist in molecular imaging of NETs. [18F]F (97% β+, 0.64Mev, T1/2=109min) has suitable half-life for peptide and lower β+-trajectory (

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Yu J

Authors: Yu J, X Q, Lu M, Li J, Y Z,

Keywords: neuroendocrine neoplasm, somatostatin receptor, [18F]AlF, JR11, TATE, PET imaging,